# Hereditary Angioedema Therapeutics Market > Hereditary Angioedema Therapeutics Market Research Report Information by Type (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, Asia Pacific, Rest of the World) - Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.72% - **2024:** $ 6.71 Billion - **2025:** $ 7.9 Billion - **2035:** $ 40.37 Billion - **Key Players:** Takeda Pharmaceutical Company Limited (JP), CSL Behring (US), Shire (US), BioCryst Pharmaceuticals, Inc. (US), Sobi (SE), Pharming Group N.V. (NL), KalVista Pharmaceuticals, Inc. (US), Acrotech Biopharma LLC (US) **Report ID:** MRFR/HC/10642-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 22, 2026 **URL:** https://www.marketresearchfuture.com/reports/hereditary-angioedema-therapeutics-market-12163 --- ## Market Summary ## Hereditary angioedema therapeutics market Overview Hereditary angioedema therapeutics market share register 7.9 billion USD in 2025, projected to grow 6.90% CAGR during the forecast period (2025 - 2034). As per MRFR analysis, the hereditary angioedema therapeutics market industry size is expected to grow from 6.71 billion USD in 2024 to 34.3 billion USD by 2034. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Hereditary Angioedema Therapeutics Market Trends** The increasing awareness of HAE among populations is a significant driver of market expansion. As per the Department of Health & Social Care, people are continuously aware of the hereditary angioedema disease and their effective treatment. The Health & Social Care Department of UK has worked with the four nations to confirm that hereditary angioedema disease patients receive better diagnosis and treatment care. In addition, many companies are also keenly interested in launching hereditary angioedema awareness programs.  For instance: in May 2023 Takeda Biopharmaceuticals India launched the hereditary angioedema awareness program “Sunrise Patient Services Program (PSP)’ for Hereditary Angioedema (HAE) patients in India. This program aims to provide patient support on four main elements including screening & diagnosis, treatment, and maintenance support applied, quality diagnostic labs, treatment compensation navigation, and lifestyle counseling support during the patient’s treatment journey.  Furthermore, In 16 May 2022, HAE Awareness Day was pragmatic across the globe to increase awareness about hereditary angioedema (HAE) and those patients the disorder affects. The aim is to raise awareness among the population as well as industry representatives, and healthcare professionals. With the help of this HAE Awareness Day developed an atmosphere for accurate and early diagnosis as well as improved HAE patient care, an Awareness Day webpage states. So that patients can get a better quality of life.  The global HAE awareness efforts were being led by HAE International (HAEi), which is an international network of patient organizations that look to improve the quality of life of HA patients. At present time HAEi supports 93 member organizations across the globe. Thus rising awareness programmes by government and private institutions play a key role in early diagnosis and better therapeutics for hereditary angioedema disease of patients which is propel the market growth of the hereditary angioedema therapeutics. ## **Hereditary Angioedema Therapeutics Market Segment Insights:** ### **Hereditary Angioedema Therapeutics Type Insights** The Market segments of Hereditary Angioedema Therapeutics, based on type, includes type I, type II . The type I segment held the majority share in 2022 in the Hereditary Angioedema Therapeutics Market revenue due to the rising prevalence of these HAE types. Patients with Type I and Type II HAE require different treatment strategies, leading to diverse therapeutic demands. . BioCryst Pharmaceuticals Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) implemented a positive opinion recommending the approval of ORLADEYO (Berotralstat) for routine prevention of repeated occurrences of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.“ ### **Hereditary Angioedema Therapeutics Drug Class Insights** The Hereditary Angioedema Therapeutics Market segmentation based on drug class includes C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others. The C1 Esterase inhibitors segment dominated the market in 2022. As the demand for C1 Esterase Inhibitors remains strong as they are considered the standard of care for acute HAE attacks. These drugs are gaining popularity as oral medications for both prophylaxis and on-demand treatment, addressing the demand for alternative treatment options. Kallikrein inhibitors are emerging as a novel class of drugs with increasing demand due to their potential effectiveness in reducing HAE attacks. ### **Hereditary Angioedema Therapeutics Treatment Insights** The Market segmentation of Hereditary Angioedema Therapeutics based on treatment includes prophylaxis, On-demand. Prophylaxis segment dominated the market in 2022 due to the prophylactic treatments, including both long-term and short-term options, are in high demand. Patients, especially those with frequent attacks, seek preventive measures to reduce the severity and frequency of HAE episodes. On-demand treatments remain a crucial segment in the HAE therapeutics market, as they provide rapid relief during acute attacks. ### **Hereditary Angioedema Therapeutics Route of Administration Insights** The Market segmentation of Hereditary Angioedema Therapeutics based on route of administration includes intravenous, subcutaneous, oral. The intravenous segment dominated the market in 2022. Intravenous treatments remain a significant preference for HAE patients during severe attacks, ensuring rapid delivery of the medication. Subcutaneous options are gaining favour for prophylactic treatments, offering patients a more convenient and less invasive route of administration. The demand for oral medications is increasing, especially for patients seeking non-invasive prophylactic solutions. ### **Hereditary Angioedema Therapeutics Distribution Channel Insights** The Market segmentation of Hereditary Angioedema Therapeutics based on distribution channel includes hospital pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment dominated the market in 2022. Hospitals continue to be a key distribution channel, ensuring immediate access to HAE medications during emergencies. Retail pharmacies cater to the needs of patients seeking ongoing prescription refills and non-urgent medication supplies. The online pharmacy segment is witnessing substantial growth, driven by the convenience and accessibility it offers to HAE patients, particularly in remote areas. **Figure 2: Hereditary Angioedema Therapeutics Market, by distribution channel, 2022 & 2032 (USD Billion)** Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review ### **Hereditary Angioedema Therapeutics****Products Regional Insights** By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Hereditary Angioedema Therapeutics market is expected to account for USD 1.4 billion in 2022 and is expected to exhibit an 14.12% CAGR during the study period. This is attributed to the market of Hereditary Angioedema therapeutics is well-established and witnesses continuous growth. This region boasts advanced healthcare facilities and high awareness of rare diseases like HAE. The demand for prophylactic treatments, especially long-term prophylaxis, remains significant, as patients prefer preventive measures to reduce the frequency and severity of attacks.  The market also observes a growing preference for selective bradykinin B2 receptor antagonists, which offer oral alternatives for both prophylaxis and on-demand treatment. Intravenous administration is prevalent for immediate relief during acute attacks in the region further fuel the growth of the market. Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 3: Hereditary Angioedema Therapeutics Market share by region 2022 & 2032 (USD billion)** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review Europe Hereditary Angioedema Therapeutics market is expected to account for the second-largest market share due to the rising research and development actvitity, rising product approval and favourable reimbursement policy for [orphan drugs](../../../reports/orphan-drugs-market-2312) older population. Further, the Germany market of Hereditary Angioedema Therapeutics is expected to hold third place for the market share, and the UK market of Hereditary Angioedema Therapeutics is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France market of Hereditary Angioedema Therapeutics will hold the 5th place for the market share. The Asia-Pacific Hereditary Angioedema Therapeutics market is expected to grow at a high growth rate from 2023 to 2032. This is due to the rising disposable income in the developing countries and availability of medical facility and medical staff,rising awareness programe launch. Moreover, China market of Hereditary Angioedema Therapeutics is expected to hold the largest market share, and the India market of Hereditary Angioedema Therapeutics is expected fastest-growing market in the Asia-Pacific region. The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the rest of the world market of Hereditary Angioedema Therapeutics. ## **Hereditary Angioedema Therapeutics Key Market Players & Competitive Insights** The presence of major market players in the Hereditary Angioedema Therapeutics Market is characterized by the presence of many international, regional, and local players. The companies are investing in R&D activities to expand their product portfolio for breast enhancement, which further drives the market growth of the Hereditary Angioedema Therapeutics. Moreover, the vendors compete based on cost, product quality, reliability, and aftermarket services and try to be the first to bring treatment for the public. It is crucial for the players to offer cost-efficient and high-quality products for Hereditary Angioedema Therapeutics to succeed in an intensely competitive market environment. One of the primary business strategies adopted by manufacturers in the global Hereditary Angioedema Therapeutics industry to benefit clients and expand the market sector of Hereditary Angioedema Therapeutics is to manufacture locally to reduce operating costs. Sanofi is a global life science company concentrating on improving access to healthcare and supporting the people throughout the continuum of care. From prevention to treatment, the company transforms scientific innovation into healthcare solutions in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, [infectious diseases](../../../reports/infectious-disease-treatments-market-1626), diabetes and cardiovascular solutions, and consumer healthcare. The company is present in more than 170 countries, and it has 37 manufacturing units in 36 countries. ### **Key Companies in the market of Hereditary Angioedema Therapeutics includes** ## **Hereditary Angioedema Therapeutics Industry Developments** **February 2021 :** KalVista (US) reported positive results in its Phase 2 clinical trial for KVD900 as an oral on-demand treatment for HAE attacks. **March 2023:**Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema.This enables the company’s ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part. ## **Hereditary Angioedema Therapeutics Market Segmentation** ### **Hereditary Angioedema Therapeutics Type Outlook** ### **Hereditary Angioedema Drug Class Outlook** ### **Hereditary Angioedema Therapeutics Treatment Outlook** ### **Hereditary Angioedema Therapeutics Route of Administration Outlook** ### **Hereditary Angioedema Therapeutics Distribution Channel Outlook** ### **Hereditary Angioedema Therapeutics Regional Outlook** North America Europe Asia-Pacific Rest of the World ## Market Drivers ### Regulatory Support and Approval Regulatory bodies are increasingly supportive of the development and approval of new therapies for hereditary angioedema, which serves as a significant driver for the Hereditary Angioedema Therapeutics Market. Streamlined approval processes and incentives for orphan drugs have encouraged pharmaceutical companies to invest in HAE therapeutics.   The recent approvals of several new treatments have not only expanded the available options for patients but have also instilled confidence in the market. This regulatory environment is conducive to innovation, allowing for faster access to life-saving therapies. As a result, the Hereditary Angioedema Therapeutics Market is likely to experience accelerated growth, with more products entering the market in the coming years. ### Advancements in Therapeutic Options Technological advancements in the development of therapeutics are driving the Hereditary Angioedema Therapeutics Market. The introduction of novel therapies, including C1-inhibitor replacement therapies and bradykinin receptor antagonists, has transformed treatment paradigms. These innovations not only improve patient outcomes but also enhance the quality of life for individuals suffering from HAE.   The market is witnessing a surge in research and development activities, with several new products entering the pipeline. For instance, recent data indicates that the market for HAE therapeutics is expected to reach USD 2 billion by 2026, underscoring the impact of these advancements on the industry. As more effective and targeted therapies become available, the landscape of the Hereditary Angioedema Therapeutics Market is likely to evolve rapidly. ### Rising Incidence of Hereditary Angioedema The increasing prevalence of hereditary angioedema (HAE) is a notable driver for the Hereditary Angioedema Therapeutics Market. Recent estimates suggest that HAE affects approximately 1 in 10,000 to 1 in 50,000 individuals, leading to a growing patient population in need of effective treatments. This rise in incidence is prompting healthcare providers and pharmaceutical companies to focus on developing innovative therapies.   As awareness of HAE expands, more patients are being diagnosed, which in turn fuels demand for specialized therapeutics. The market is projected to grow significantly, with a compound annual growth rate (CAGR) of around 8% over the next several years, reflecting the urgent need for effective management options in the Hereditary Angioedema Therapeutics Market. ### Growing Patient Advocacy and Support Groups The rise of patient advocacy and support groups is significantly influencing the Hereditary Angioedema Therapeutics Market. These organizations play a vital role in raising awareness about HAE, educating patients, and advocating for better treatment options. Their efforts have led to increased visibility of the condition, prompting healthcare providers to prioritize HAE management.   Furthermore, these groups often collaborate with pharmaceutical companies to facilitate [clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787) and gather patient feedback, which can enhance therapeutic development. As patient engagement continues to grow, the demand for effective treatments is likely to increase, thereby driving the Hereditary Angioedema Therapeutics Market forward. ### Increased Investment in Research and Development Investment in research and development (R&D) for hereditary angioedema therapies is a crucial driver for the Hereditary Angioedema Therapeutics Market. Pharmaceutical companies are allocating substantial resources to explore new treatment modalities and improve existing therapies.   This focus on R&D is driven by the unmet medical needs of HAE patients and the potential for lucrative returns on investment. Recent reports indicate that R&D spending in the HAE sector is expected to increase by over 15% annually, reflecting the industry's commitment to innovation. As more companies enter the market and competition intensifies, the landscape of the Hereditary Angioedema Therapeutics Market is poised for transformation, with a plethora of new options for patients. ## Future Outlook The Hereditary Angioedema Therapeutics Market size is projected to reach USD 6.71 Billion by 2035, growing at a CAGR of 17.72%, driven by increasing awareness, innovative therapies, and expanding patient populations. **New opportunities:** - Development of personalized gene therapies for targeted treatment. Expansion of telehealth services for remote patient monitoring. Strategic partnerships with biotech firms for innovative drug development. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in therapeutic solutions. ## Segment Insights ### By Type: Type I (Largest) vs. Type II (Fastest-Growing) The Hereditary Angioedema Therapeutics Market is prominently influenced by two major types: Type I and Type II. Type I currently holds a significant portion of the market share, benefiting from its established treatment protocols and higher patient prevalence. On the other hand, Type II, while smaller in share, is rapidly gaining traction due to ongoing research and development, leading to new therapeutic options that cater to varying patient needs. Type I: Dominant vs. Type II: Emerging Type I remains the dominant category within the Hereditary Angioedema Therapeutics Market, driven by its broader recognition among healthcare providers and availability of established treatment modalities. However, Type II is emerging as a vital segment, with an increasing focus on specialized therapies that address specific patient populations. The advancements in clinical trials and innovative drug formulations are propelling Type II toward faster growth, showcasing its potential to attract new investments and drive market expansion, catering to previously underserved patients in the therapeutic landscape. ### By Drug Class: C1 Esterase Inhibitor (Largest) vs. Selective Bradykinin B2 Receptor Antagonist (Fastest-Growing) In the Hereditary Angioedema Therapeutics Market, the distribution of market share among various drug classes reveals that C1 Esterase Inhibitors hold the largest share due to their established efficacy and long-standing presence in treatment protocols. Following closely, Selective Bradykinin B2 Receptor Antagonists are gaining prominence, especially among newer treatment regimens. Kallikrein Inhibitors and other therapeutic options currently represent smaller fragments of the market, yet their roles in comprehensive treatment strategies are evolving, especially as new clinical data emerges. C1 Esterase Inhibitor (Dominant) vs. Selective Bradykinin B2 Receptor Antagonist (Emerging) C1 Esterase Inhibitors have firmly established themselves as the dominant therapeutic class for Hereditary Angioedema treatment, primarily because of their targeted mechanism and clinical effectiveness in preventing angioedema attacks. Their reliability stems from years of clinical use, making them the standard in therapeutic approaches. On the other hand, Selective Bradykinin B2 Receptor Antagonists are emerging as a potent alternative, particularly favored for their safety profiles and convenience of administration. As these agents continue to receive clinical validation and regulatory approval, their market presence is expected to accelerate, attracting both physician adoption and patient preference for innovative treatment strategies. ### By Treatment: Prophylaxis (Largest) vs. On-demand (Fastest-Growing) The 'Treatment' segment of the Hereditary Angioedema Therapeutics Market is primarily divided into prophylaxis and on-demand options. Currently, prophylactic treatments command the largest share, providing patients with consistent prevention against attacks. In contrast, on-demand treatments have been gaining traction, catering to the needs of patients seeking immediate relief during angioedema episodes. This distribution highlights the balancing act between chronic management and acute intervention, with each segment playing a crucial role in patient care. Treatment: Prophylaxis (Dominant) vs. On-demand (Emerging) Prophylaxis represents the dominant treatment approach in the market share, focusing on the prevention of angioedema attacks, thereby improving the quality of life for patients. These therapies are designed to minimize the frequency and severity of episodes. On the other hand, the on-demand treatment segment is emerging rapidly, driven by the increasing need for immediate management of acute attacks. Patients are showing a growing preference for these therapies due to their convenience and quick relief, influencing market dynamics. Together, both segments reflect a comprehensive strategy in managing hereditary angioedema, with prophylactic treatments ensuring ongoing stability and on-demand therapies providing critical short-term relief. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) In the Hereditary Angioedema Therapeutics Market, the distribution of market share among the various routes of administration reveals key insights into consumer preferences and treatment outcomes. Currently, intravenous administration holds the largest market share, as it is often associated with rapid and effective response in emergency situations. In contrast, subcutaneous delivery is gaining traction due to its convenience for patients and ease of administration, which contributes to its growth. Administration Route: Intravenous (Dominant) vs. Subcutaneous (Emerging) Intravenous administration is recognized as the dominant route in the market, primarily due to its effectiveness in acute care settings where immediate results are crucial for patients with Hereditary Angioedema. This method allows for fast action and is often preferred in hospital environments. On the other hand, subcutaneous administration is emerging as a favorable alternative as it provides greater flexibility for home-based treatment, thereby enhancing patient compliance. The growing trend toward patient-centric care models and the development of innovative formulations for self-administration are anticipated to drive the preferred shift towards subcutaneous options in the near future. ### By Distribution Channel: Retail Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing) In the Hereditary Angioedema Therapeutics Market, the distribution channels exhibit significant differences in market share. Retail pharmacies hold the largest share, serving as a crucial point for patients seeking access to necessary therapies. Hospital pharmacies also play an essential role, accommodating patients who require immediate and specialized care. Online pharmacies are emerging, showing increased penetration as patients seek convenience and better pricing for their medications, which is gradually reshaping the landscape of distribution for these therapeutics. Growth trends indicate a shift towards online pharmacies driven by increasing digitalization and a preference for home delivery services. Consumers are becoming more inclined to use these platforms due to their accessibility and ease of use. Retail pharmacies continue to thrive, supported by strong relationships with healthcare providers and insurance companies, while hospital pharmacies remain vital for acute care settings. As patient preferences evolve, the success of online pharmacies symbolizes a pivotal change in purchasing behavior within the market, offering opportunities for expansion, particularly among younger, tech-savvy demographics. Retail Pharmacy (Dominant) vs. Online Pharmacy (Emerging) The retail pharmacy segment is characterized by its extensive geographical reach and the personalized service offered to patients. These pharmacies are often the first point of contact for patients needing hereditary angioedema therapeutics, benefiting from a strong community presence and trusted relationships with healthcare professionals. Retail pharmacies ensure timely access to medications, offering a wide range of products and often providing consultation services to assist patients with their treatment plans. Meanwhile, online pharmacies are emerging as a compelling alternative, driven by technological advancements and changing consumer behaviors. They appeal to patients seeking convenience, competitive prices, and a broader selection of medications, albeit often facing regulatory scrutiny and challenges in terms of trust and delivery times. As both channels evolve, they will play distinct yet complementary roles in the market. ## Regional Market Share Analysis ### North America : Leading Market for Innovation North America leads in the Hereditary Angioedema Therapeutics Market Size, accounting for over 59.61% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, high prevalence of the condition, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring rapid approval of innovative therapies. The United States is the primary contributor, with key players such as Takeda Pharmaceutical Company Limited and BioCryst Pharmaceuticals leading the charge. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech firms, all striving to capture market share through innovative solutions and strategic partnerships. The presence of a robust healthcare system facilitates patient access to these therapies, enhancing overall market dynamics. ### Europe : Emerging Market with Growth Potential Europe Hereditary Angioedema Therapeutics Market was valued at USD 2.01 Billion in 2024, making it the second-largest regional market with a 30% share. The region is witnessing increased demand driven by rising awareness, improved diagnostic capabilities, and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in expediting the approval of new treatments, thereby enhancing market accessibility. Leading countries include Germany, France, and the UK, where healthcare systems are increasingly prioritizing rare diseases. Key players like CSL Behring and Pharming Group N.V. are actively involved in expanding their product offerings. The competitive landscape is evolving, with a focus on innovative therapies and patient-centric solutions, ensuring that Europe remains a vital player in the global market. ### Asia-Pacific : Rapidly Growing Market Segment Asia-Pacific is an emerging powerhouse in the Hereditary Angioedema therapeutics market, currently holding about 10% of the global market share. The region is characterized by increasing healthcare expenditure, rising awareness of rare diseases, and a growing patient population. Regulatory bodies are beginning to streamline approval processes, which is expected to further boost market growth in the coming years. Countries like Japan and Australia are leading the charge, with a growing number of local and international players entering the market. Companies such as KalVista Pharmaceuticals and Acrotech Biopharma are focusing on expanding their presence in this region. The competitive landscape is becoming more dynamic, with collaborations and partnerships aimed at enhancing product offerings and improving patient access to therapies. ### Middle East and Africa : Untapped Market Potential The Middle East and Africa represent a nascent market for Hereditary Angioedema therapeutics, holding approximately 5% of the global market share. The region faces challenges such as limited healthcare infrastructure and low awareness of rare diseases. However, there is significant potential for growth driven by increasing investments in healthcare and rising demand for specialized treatments. Regulatory frameworks are gradually evolving to support the introduction of new therapies. Countries like South Africa and the UAE are beginning to see a rise in healthcare initiatives aimed at rare diseases. The competitive landscape is still developing, with few key players currently active. However, as awareness grows and healthcare systems improve, opportunities for both local and international companies are expected to expand, paving the way for future market growth. ## Competitive Benchmarking The Hereditary Angioedema Therapeutics Market is characterized by a dynamic competitive landscape, driven by increasing awareness of the condition and advancements in treatment options. Key players such as Takeda Pharmaceutical Company Limited (Japan), CSL Behring (US), and BioCryst Pharmaceuticals, Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Takeda (Japan) focuses on innovation through the development of novel therapies, while CSL Behring (US) emphasizes strategic partnerships to expand its product offerings. BioCryst Pharmaceuticals, Inc. (US) is leveraging its expertise in rare diseases to carve out a niche, indicating a trend towards specialization among competitors.   The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. This collective approach not only strengthens their operational capabilities but also fosters a competitive environment where agility and adaptability are paramount. In August 2025, Takeda Pharmaceutical Company Limited (Japan) announced the launch of a new treatment specifically targeting patients with hereditary angioedema, which is expected to significantly improve patient outcomes. This strategic move underscores Takeda's commitment to innovation and its proactive approach to addressing unmet medical needs in the market.   The introduction of this therapy may enhance Takeda's competitive edge by solidifying its reputation as a leader in the field. In July 2025, BioCryst Pharmaceuticals, Inc. (US) entered into a collaboration with a leading biotechnology firm to develop a next-generation therapy for hereditary angioedema. This partnership is likely to accelerate the development timeline and broaden the therapeutic options available to patients. Such collaborations reflect a growing trend towards synergistic alliances that can leverage complementary strengths to drive innovation. In September 2025, CSL Behring (US) expanded its manufacturing capabilities in response to increasing global demand for its therapies. This expansion not only enhances production capacity but also positions CSL Behring to better serve diverse markets.   The strategic focus on scaling operations indicates a recognition of the need for supply chain reliability in a competitive landscape. As of October 2025, the competitive trends in the Hereditary Angioedema Therapeutics Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will increasingly hinge on innovation and technological advancements rather than solely on price. The emphasis on supply chain reliability and the ability to deliver cutting-edge therapies will likely define the future landscape of this market. ## Recent News & Developments **February 2021 :** KalVista (US) reported positive results in its Phase 2 clinical trial for KVD900 as an oral on-demand treatment for HAE attacks. **March 2023:**Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema.This enables the company’s ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part. ## Report Scope | MARKET SIZE 2024 | 6.71(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.899(USD Billion) | | MARKET SIZE 2035 | 40.37(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.72% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Takeda Pharmaceutical Company Limited (JP), CSL Behring (US), Shire (US), BioCryst Pharmaceuticals, Inc. (US), Sobi (SE), Pharming Group N.V. (NL), KalVista Pharmaceuticals, Inc. (US), Acrotech Biopharma LLC (US) | | Segments Covered | Type, Drug Class, Treatment, Route of Administration, Distribution Channel, Region | | Key Market Opportunities | Advancements in gene therapy and biologics enhance treatment options in the Hereditary Angioedema Therapeutics Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Hereditary Angioedema Therapeutics Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Hereditary Angioedema Therapeutics Market?** A: The market valuation was 6.71 USD Billion in 2024. **Q: What is the projected market size for the Hereditary Angioedema Therapeutics Market by 2035?** A: The market is projected to reach 40.37 USD Billion by 2035. **Q: What is the expected CAGR for the Hereditary Angioedema Therapeutics Market during the forecast period 2025 - 2035?** A: The expected CAGR is 17.72% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the Hereditary Angioedema Therapeutics Market?** A: Key players include Takeda Pharmaceutical Company Limited, CSL Behring, Shire, BioCryst Pharmaceuticals, Inc., Sobi, Pharming Group N.V., KalVista Pharmaceuticals, Inc., and Acrotech Biopharma LLC. **Q: What are the main drug classes in the Hereditary Angioedema Therapeutics Market?** A: The main drug classes include C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others. **Q: How does the market segment by treatment type for Hereditary Angioedema?** A: The market segments into Prophylaxis and On-demand treatments, with valuations of 3.36 and 3.35 USD Billion respectively in 2024. **Q: What routes of administration are prevalent in the Hereditary Angioedema Therapeutics Market?** A: The prevalent routes of administration include Intravenous, Subcutaneous, and Oral, with respective valuations of 1.34, 2.01, and 3.36 USD Billion in 2024. **Q: What distribution channels are utilized in the Hereditary Angioedema Therapeutics Market?** A: Distribution channels include Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy, with valuations of 2.68, 2.01, and 1.02 USD Billion respectively in 2024. **Q: What are the projected market trends for Type I and Type II Hereditary Angioedema?** A: Type I and Type II are projected to have valuations of 3.36 and 3.35 USD Billion respectively in 2024, indicating a balanced market. **Q: How is the competitive landscape evolving in the Hereditary Angioedema Therapeutics Market?** A: The competitive landscape is evolving with key players like Takeda and CSL Behring leading the market, suggesting a dynamic environment for innovation. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hereditary-angioedema-therapeutics-market-12163*